Create issue ticket

173 Possible Causes for Mutation in the EGFR Gene

  • Bronchioloalveolar Carcinoma

    Although adenocarcinomas of the lung are associated with epidermal growth factor receptor (EGFR) gene mutations and sensitivity to EGFR tyrosine kinase inhibitors, it remains[ncbi.nlm.nih.gov] Tyrosine kinase inhibitors may have a role in BAC in the absence of EGFR gene mutations.[ncbi.nlm.nih.gov] We examined 141 non–small cell lung cancers (NSCLCs), including 118 adenocarcinomas, for mutations in exons 19 and 21 of the EGFR gene together with mutations in codon 12[doi.org]

  • Restless Legs Syndrome

    Notably, samples with mutations in several receptor tyrosine kinase genes do not harbour any mutations in EGFR ( Fig. 3 ).[doi.org] Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.[doi.org] The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4 ; multiple ephrin receptor genes, notably EPHA3 ; vascular endothelial growth factor[doi.org]

  • Non-Small Cell Lung Carcinoma

    The discovery that patients with exon 19 and 21 mutations in the epidermal growth factor receptor gene EGFR have around an 80% response rate to gefitinib (Iressa ; AstraZeneca[doi.org] For example, EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, are approved for patients with mutations in the EGFR gene; it is now widely accepted[doi.org] Another altered kinase gene involves MET. 'Driver' mutations lead to constitutive activation of mutant signaling proteins that induce and sustain tumorigenesis.[mycancergenome.org]

  • Alzheimer Disease

    Analysis of gene copy numbers of the EGFR has not consistently shown that this mutation is also involved in a larger response to gefitinib in the treatment of non small lung[doi.org] The responsible mutations include deletions in exon 19 (46%), duplication and insertion in exon 20 (9%) or point mutations in exon 21 (39%).[doi.org] 10-15% of the patients in Western countries show these mutations. 71% of the patients carrying the mutation respond to treatment, but only 1% of the patients without this mutation[doi.org]

  • Squamous Cell Carcinoma of the Lung

    The first targeted treatments for lung adenocarcinoma, erlotinib (Tarceva) and gefitinib (Iressa), were aimed at mutations in the EGFR gene.[broadinstitute.org] gene mutations (NEJ002).[doi.org] […] in the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) gene rearrangements, survival for patients with non-squamous metastatic NSCLC has significantly[targetedonc.com]

  • Pulmonary Blastoma

    METHODS: 5 PBs were analysed for EGFR, HER2, c-KIT, and β-catenin expression, as well as for mutations in EGFR, c-KIT, k-ras and the β-catenin gene (CTNNB1).[ncbi.nlm.nih.gov] […] analysis of the p53, EGFR, KRAS and beta-catenin genes were performed against the epithelial and mesenchymal components in the primary tumor and a metastatic tumor in a case[ncbi.nlm.nih.gov] Mutations in several genes (including TP53, CTNNB1 and EGFR ) may be identified in some PB tumors.[orpha.net]

  • Familial Adenomatous Polyposis

    A Salapura, S Knezevic Usaj, Z Eri, L Tadic Latinovic Vojnosanitetski pregled 72 (4), 2015 2015 PROTEIN EXPRESSION, GENE AMPLIFICATION, EGFR MUTATIONS, AND LUNG CARCINOMA[scholar.google.com]

  • Adenocarcinoma of the Breast

    Basal-like MBC lacking EGFR and KIT activating mutations may exhibit high EGFR copy numbers [ 29 ].[journals.plos.org] Reis-Filho al [ 28 ] reported EGFR gene amplification in 37% of the MBCs with EGFR overexpression.[journals.plos.org]

  • Carcinoma of the Breast

    Basal-like MBC lacking EGFR and KIT activating mutations may exhibit high EGFR copy numbers [ 29 ].[journals.plos.org] Reis-Filho al [ 28 ] reported EGFR gene amplification in 37% of the MBCs with EGFR overexpression.[journals.plos.org]

  • Colon Cancer

    For instance, anti-cancer medications that target the EGFR protein, such as, Cetuximab and Panitumumab, will not be effective in people who have a KRAS or BRAF gene mutation[oncolink.org]

Further symptoms